health biotech news today obesity drugs glp-1 The next phase of the drug race CVS obesity drug deal puts

The mechanism is straightforward: GLP-1 RAs enhance glucose-dependent insulin secretion, and stacking that on top of glucose-independent insulin release from exogenous insulin or sulfonylureas removes the glucose-dependent safety brake

More specifically, it targeted vaginal microbiome health and pH levels to support freshness and odor. As OB-GYN and female pelvic surgeon Dr

Over 75% of health plans and over 50% of employers are moderately or very concerned about off-label use of GLP-1s approved for type 2 diabetes, but awareness of how much current spend is off-label is notably lower: nearly half of employers and a quarter of health plans are unsure

DPP-4 Inhibition Has Beneficial Effects on the Heart after Myocardial Infarction

PeerJ 9, e11128